Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use

Inactive Publication Date: 2005-01-06
KALINSKI PAWEL
View PDF13 Cites 62 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0019] The present invention discloses novel dendritic cell (“DC”) maturation-inducing cytokine cocktails, and means for inducting type-1 polarized dendritic cells (“DC1s”) in serum-free conditions which enhance the desirable properties of DC1s generated in serum-supplemented cultures. The invention further discloses the use of IFNγ and other ligands of the IFNγ receptor, in combination with IFNα (or other type I interferons, such as IFNβ, known to bind to the same receptor), poly I:C, and other IFNα (and IFNβ) inducers to enhance the IL-12-producing properties of DCs. The invention also discloses the use of DC1s to induce Ag-specific T cells against tumors, intracellular pathogens, and atopic allergens for active and passive immunotherapy, immunomonitoring and research purposes. More specifically, the present invention discloses type-1 polarized DCs (DC1s) that have a unique combination of a fully-mature status and an elevated, instead of “exhausted”, ability to produce IL-12p70. These properties allow these DC1s to selectively induce high-intensity Th1-, CTL-, and NK cell-mediated type-1 immune responses, including those desirable in the treatment of cancer. Another preferred embodiment of the present invention shows that the inclusion of IFNα and / or poly-I:C to the “classical” DC1-inducing cocktail (TNFα / IL-1β / IFNγ) allows for the generation of fully-mature DC1s in serum- free AIM-V medium. In other preferred embodiments, the present invention discloses serum-free protocols of DC1 generation that facilitate the clinical application of DC1-based therapies and the identification of novel factors involved in the induction of Th1-, CTL-, and NK cell responses by DC1.

Problems solved by technology

Unfortunately, the maturation stage of DCs obtained in the currently-available protocols inversely correlates with their ability to produce IL-12p70 (Kalinski et al., 1999, Langenkamp et al., 2000), the cytokine with powerful anticancer Th1-and CTL-inducing properties (Trinchieri, 1998b); (Shurin et al., 1997).
However, use of IL-12 transduced DC in humans creates substantial logistic problems.
It also carries potential risks associated with the administration of genetically-manipulated material and the risks of direct IL-12 toxicity and of deregulating the immune system due to uncontrolled IL-12 production.
Specifically, none of the patents disclose or teach the combination of type I and type II interferons (such as IFNα and IFNγ), as a part of the cytokine cocktail used to produce fully mature DCs with high IL-12 producing capacity.
Thus, despite the efforts of many, the desirable combination of high immunostimulatory activity with a high capacity to produce IL-12p70 could not be attained by all previous DC-based vaccines which have employed either mature DCs exhibiting high stimulatory / low IL-12-secreting functions or immature DCs that display low stimulatory / high IL-12 secretion functions.
Unfortunately, the original DC1-inducing cytokine cocktail, composed of IL-1β, TNFα, and IFN-γ (Vieira et al 2000), does not allow for the induction of DC1s in serum-free media, which is desirable for clinical application.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use
  • Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use
  • Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0020] To boost the immunogenic capacity of DCs and their ability to induce high-intensity Th1 and CTL-mediated type-1 immune responses, the present invention combines within one DC type a fully-mature status and a high ability to produce high levels of IL-12p70. In contrast to current methodologies in which the final maturation of DCs induced by typical stimuli is associated with reduced ability to produce IL-12 (Kalinski et al., 1999, Langenkamp et al., 2000), the present invention provides for concomitant exposure of immature DC to a maturation-inducing stimulus and to IFNγ which results in a strong enhancement of the subsequent ability of mature DC to produce IL-12 and to induce Th1-dominated responses (Vieira et al., 2000, Mailliard et al., 2002), and more specifically the cancer-specific CTL responses.

[0021] Further, although current DC1-inducing protocols are ineffective in serum-free conditions, the present invention provides that IFNα, a member of type I interferon family,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses novel dendritic cell maturation-inducing cytokine cocktails, and methods for inducting type-1 polarized dendritic cells in serum-free conditions which enhance the desirable properties of DC1s generated in serum-supplemented cultures. The invention further discloses methods and systems using IFNγ and other ligands of the IFNγ receptor, in combination with IFNα (or other type I interferons), poly I:C, and other IFNα (and IFNβ) inducers to enhance the IL-12-producing properties of dendritic cells. More specifically, the present invention discloses type-1 polarized dendritic cells that have a unique combination of a fully-mature status and an elevated, instead of “exhausted”, ability to produce IL-12p70. allows for the generation of fully-mature DC1s in serum-free AIM-V medium. The invention discloses systems that use the foregoing products and methods to facilitate the clinical application of DC1-based vaccines and the identification of novel factors involved in the induction of Th1 and CTL responses by DC1.

Description

[0001] This application claims priority from U.S. application Ser. No. 60 / 468,760, filed May 8, 2003, entitled “MATURE TYPE-1 POLARIZED DENDRITIC CELLS WITH ENHANCED IL-12 PRODUCTION AND METHODS OF SERUM-FREE PRODUCTION AND USE”.STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT [0002] Portions of the present invention were made with support of the United States Government via a grant from the National Cancer Institute under grant number 1R01CA82016. The U.S. Government may therefore have certain rights in the invention.BACKGROUND [0003] 1. Field of the Invention [0004] The invention relates to methods of generating mature dendritic cells with enhanced IL-12 production and compositions and systems for such dendritic cells. [0005] 2. Discussion of the Background [0006] Dendritic cells (DCs), the most potent antigen presenting cells, are effective inducers of protective immunity against infectious diseases and cancer (Banchereau & Steinman 199...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/00C12N5/0784
CPCA61K2039/5154A61K2039/57C12N5/0639C12N5/0634C12N2501/056C12N2501/23C12N2501/25C12N5/064A61P37/00Y02A50/30A61K39/4622A61K39/464838A61K39/4648A61K39/4615A61K39/464839A61K39/46433A61K39/4641A61K39/4644A61K39/4621
Inventor KALINSKI, PAWEL
Owner KALINSKI PAWEL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products